-transparent.png){kind=logo}
BRL 42715, a novel beta-lactamase inhibitor, was evaluated for its capacity to inhibit cephalosporinases. BRL 42715 was effective in potentiating the activity of antibiotics against clinical isolates of Enterobacteriaceae that produced high levels of cephalosporinases. This correlated well with the very low 50% inhibition values (< 0.004 mg/L) of BRL 42715 for cephalosporinases extracted from different species. When compared in vitro to clavulanic acid, sulbactam, and tazobactam, BRL 42715 was the most efficient inhibitor of cephalosporinase.
Related Publications
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
June 1993,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
September 1989,
Antimicrobial agents and chemotherapy,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
January 1991,
Chemotherapy,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
January 1993,
Microbios,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
September 1991,
Antimicrobial agents and chemotherapy,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
November 1994,
The Biochemical journal,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
June 2012,
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
January 1993,
The Journal of antimicrobial chemotherapy,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
August 2018,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
X Y Zhou, and
M D Kitzis, and
J F Acar, and
L Gutmann
October 1994,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
